Influenza Vaccination Campaign Starts Next Week

03/22/2024

The 26th National Influenza Vaccination Campaign will begin in Caçapava next Monday, March 25th, and will continue until May 31st, 2024, according to the Ministry of Health’s schedule.

The vaccine is considered the best prevention strategy against influenza and has the ability to promote immunity during the period of greatest circulation.
of viruses, reducing the worsening of the disease, hospitalizations and the number of deaths, in addition to reducing the burden on health services. Symptoms can be confused with those of Covid-19.

For now, people belonging to the priority groups indicated by the Ministry of Health can be immunized, which are:

– Children aged 6 months to 5 years, 11 months and 29 days;

– Pregnant and postpartum women;

– Indigenous, riverside and quilombola peoples;

– Health workers;

– Elderly people aged 60 or over;

– Teachers from public and private schools;

– People with chronic non-communicable diseases and other special clinical conditions;

– People with permanent disabilities;

– Professionals from the security and rescue forces and the armed forces;

– Truck drivers;

– Urban and long-distance public road passenger transport workers;

– Port workers;

– Prison system employees;

– Adolescents and young people aged 12 to 21 years old undergoing socio-educational measures;

– Population deprived of liberty;

– Homeless population.

Vaccination against Influenza 2024 will be available in the vaccination rooms of the following units:
– ESF Nova Caçapava

– ESF Caçapava Velha

– ESF Vila Paraíso

– ESF Piedade – ESF Vila Menino Jesus

– UBS Health Center

Time: 8:30 am to 3:30 pm (except ESF Nova Caçapava, which operates from 7am to 7pm) or until the doses are finished

Influenza is an acute infection that affects the respiratory system, with high transmissibility and global distribution, with a tendency to spread easily in seasonal epidemics, as occurs in colder seasons, and can also cause pandemics.

The Ministry of Health’s goal is to immunize at least 90% of the so-called priority group, that is, those individuals most susceptible to the virus and who become vectors of the disease.